1. Home
  2. ALLO vs STIM Comparison

ALLO vs STIM Comparison

Compare ALLO & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • STIM
  • Stock Information
  • Founded
  • ALLO 2017
  • STIM 2003
  • Country
  • ALLO United States
  • STIM United States
  • Employees
  • ALLO N/A
  • STIM N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • STIM Medical/Dental Instruments
  • Sector
  • ALLO Health Care
  • STIM Health Care
  • Exchange
  • ALLO Nasdaq
  • STIM Nasdaq
  • Market Cap
  • ALLO 252.9M
  • STIM 224.8M
  • IPO Year
  • ALLO 2018
  • STIM 2018
  • Fundamental
  • Price
  • ALLO $1.44
  • STIM $2.89
  • Analyst Decision
  • ALLO Buy
  • STIM Strong Buy
  • Analyst Count
  • ALLO 12
  • STIM 2
  • Target Price
  • ALLO $8.80
  • STIM $7.00
  • AVG Volume (30 Days)
  • ALLO 2.9M
  • STIM 1.2M
  • Earning Date
  • ALLO 11-06-2025
  • STIM 11-11-2025
  • Dividend Yield
  • ALLO N/A
  • STIM N/A
  • EPS Growth
  • ALLO N/A
  • STIM N/A
  • EPS
  • ALLO N/A
  • STIM N/A
  • Revenue
  • ALLO N/A
  • STIM $111,106,000.00
  • Revenue This Year
  • ALLO N/A
  • STIM $105.70
  • Revenue Next Year
  • ALLO $100.00
  • STIM $11.77
  • P/E Ratio
  • ALLO N/A
  • STIM N/A
  • Revenue Growth
  • ALLO N/A
  • STIM 54.17
  • 52 Week Low
  • ALLO $0.86
  • STIM $0.52
  • 52 Week High
  • ALLO $3.78
  • STIM $5.92
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 64.79
  • STIM 45.96
  • Support Level
  • ALLO $1.29
  • STIM $2.58
  • Resistance Level
  • ALLO $1.43
  • STIM $3.01
  • Average True Range (ATR)
  • ALLO 0.07
  • STIM 0.18
  • MACD
  • ALLO 0.02
  • STIM 0.04
  • Stochastic Oscillator
  • ALLO 78.17
  • STIM 70.11

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

About STIM Neuronetics Inc.

Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.

Share on Social Networks: